The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
Publication: AIDS Research and Human Retroviruses
Volume 28, Issue Number 11
Abstract
The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1 acquisition. Plasma collected from HIV-1-uninfected trial participants completing all injections with ALVAC-HIV (vCP1521) prime and AIDSVAX B/E boost were tested for antibody responses against HIV-1 gp120 envelope (Env). Peptide microarray analysis from six HIV-1 subtypes and group M consensus showed that vaccination induced antibody responses to the second variable (V2) loop of gp120 of multiple subtypes. We further evaluated V2 responses by ELISA and surface plasmon resonance using cyclic (Cyc) and linear V2 loop peptides. Thirty-one of 32 vaccine recipients tested (97%) had antibody responses against Cyc V2 at 2 weeks postimmunization with a reciprocal geometric mean titer (GMT) of 1100 (range: 200–3200). The frequency of detecting plasma V2 antibodies declined to 19% at 28 weeks post-last injection (GMT: 110, range: 100–200). Antibody responses targeted the mid-region of the V2 loop that contains conserved epitopes and has the amino acid sequence KQKVHALFYKLDIVPI (HXB2 Numbering sequence 169–184). Valine at position 172 was critical for antibody binding. The frequency of V3 responses at 2 weeks postimmunization was modest (18/32, 56%) with a GMT of 185 (range: 100–800). In contrast, naturally infected HIV-1 individuals had a lower frequency of antibody responses to V2 (10/20, 50%; p=0.003) and a higher frequency of responses to V3 (19/20, 95%), with GMTs of 400 (range: 100–3200) and 3570 (range: 200–12,800), respectively. RV144 vaccination induced antibodies that targeted a region of the V2 loop that contains conserved epitopes. Early HIV-1 transmission events involve V2 loop interactions, raising the possibility that anti-V2 antibodies in RV144 may have contributed to viral inhibition.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Rerks-Ngarm SPitisuttithum PNitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandN Engl J Med2009361232209-2220. 1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209–2220.
2.
Kim JHRerks-Ngarm SExcler JLMichael NL. HIV vaccines: Lessons learned and the way forwardCurr Opin HIV AIDS201055428-434. 2. Kim JH, Rerks-Ngarm S, Excler JL, and Michael NL: HIV vaccines: Lessons learned and the way forward. Curr Opin HIV AIDS 2010;5(5):428–434.
3.
Haynes BFLiao HXTomaras GD. Is developing an HIV-1 vaccine possible?Curr Opin HIV AIDS201055362-367. 3. Haynes BF, Liao HX, and Tomaras GD: Is developing an HIV-1 vaccine possible? Curr Opin HIV AIDS 2010;5(5):362–367.
4.
Nitayaphan SPitisuttithum PKarnasuta C et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adultsJ Infect Dis20041904702-706. 4. Nitayaphan S, Pitisuttithum P, Karnasuta C, et al.: Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004;190(4):702–706.
5.
Karnasuta CParis RMCox JH et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in ThailandVaccine200523192522-2529. 5. Karnasuta C, Paris RM, Cox JH, et al.: Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005;23(19):2522–2529.
6.
Cao HKaleebu PHom D et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine StudyJ Infect Dis20031876887-895. 6. Cao H, Kaleebu P, Hom D, et al.: Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis 2003;187(6):887–895.
7.
Gupta KHudgens MCorey L et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022AJ Acquir Immune Defic Syndr2002293254-261. 7. Gupta K, Hudgens M, Corey L, et al.: Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002;29(3):254–261.
8.
Evans TGKeefer MCWeinhold KJ et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersJ Infect Dis19991802290-298. 8. Evans TG, Keefer MC, Weinhold KJ, et al.: A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999;180(2):290–298.
9.
Belshe RBGorse GJMulligan MJ et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation GroupAIDS199812182407-2415. 9. Belshe RB, Gorse GJ, Mulligan MJ, et al.: Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998;12(18):2407–2415.
10.
Pitisuttithum PGilbert PGurwith M et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, ThailandJ Infect Dis2006194121661-1671. 10. Pitisuttithum P, Gilbert P, Gurwith M, et al.: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194(12):1661–1671.
11.
Flynn NMForthal DNHarro CD et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infectionJ Infect Dis20051915654-665. 11. Flynn NM, Forthal DN, Harro CD, et al.: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191(5):654–665.
12.
Gilbert PBPeterson MLFollmann D et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trialJ Infect Dis20051915666-677. 12. Gilbert PB, Peterson ML, Follmann D, et al.: Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005;191(5):666–677.
13.
Hessell AJPoignard PHunter M et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaquesNat Med2009158951-954. 13. Hessell AJ, Poignard P, Hunter M, et al.: Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009;15(8):951–954.
14.
Shibata RIgarashi THaigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeysNat Med199952204-210. 14. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999;5(2):204–210.
15.
Baba TWLiska VHofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infectionNat Med200062200-206. 15. Baba TW, Liska V, Hofmann-Lehmann R, et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6(2):200–206.
16.
Mascola JRStiegler GVanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodiesNat Med200062207-210. 16. Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6(2):207–210.
17.
Barouch DHLiu JLi H et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysNature201248289-93. 17. Barouch DH, Liu J, Li H, et al.: Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012;482:89–93.
18.
Barnett SWBurke BSun Y et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvantJ Virol201084125975-5985. 18. Barnett SW, Burke B, Sun Y, et al.: Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010;84(12):5975–5985.
19.
Lambert JSMofenson LMFletcher CV et al. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study GroupJ Infect Dis19971752283-291. 19. Lambert JS, Mofenson LM, Fletcher CV, et al.: Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis 1997;175(2):283–291.
20.
Haynes BFGilbert PBMcElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trialN Engl J Med2012366141275-1286. 20. Haynes BF, Gilbert PB, McElrath MJ, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366(14):1275–1286.
21.
Montefiori DCKarnasuta CHuang Y et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsJ Infect Dis20122063431-441. 21. Montefiori DC, Karnasuta C, Huang Y, et al.: Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012;206(3):431–441.
22.
Chen BVogan EMGong H et al. Structure of an unliganded simian immunodeficiency virus gp120 coreNature20054337028834-841. 22. Chen B, Vogan EM, Gong H, et al.: Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005;433(7028):834–841.
23.
Arthos JCicala CMartinelli E et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cellsNat Immunol200893301-309. 23. Arthos J, Cicala C, Martinelli E, et al.: HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008;9(3):301–309.
24.
Cicala CMartinelli EMcNally JP et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1Proc Natl Acad Sci USA20091064920877-20882. 24. Cicala C, Martinelli E, McNally JP, et al.: The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA 2009;106(49):20877–20882.
25.
Walker LMSimek MDPriddy F et al. A limited number of antibody specificities mediate broad, potent serum neutralization in selected HIV-1 infected individualsPLoS Pathog201068. 25. Walker LM, Simek MD, Priddy F, et al.: A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010;6(8).
26.
Doores KJBurton DR. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16J Virol2010842010510-10521. 26. Doores KJ and Burton DR: Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 2010;84(20):10510–10521.
27.
Hu GLiu JTaylor KARoux KH. Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loopJ Virol20118562741-2750. 27. Hu G, Liu J, Taylor KA, and Roux KH: Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J Virol 2011;85(6):2741–2750.
28.
Spurrier BSampson JMTotrov M et al. Structural analysis of human and macaque mAbs 2909 and 2.5B: Implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120Structure2011195691-699. 28. Spurrier B, Sampson JM, Totrov M, et al.: Structural analysis of human and macaque mAbs 2909 and 2.5B: Implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120. Structure 2011;19(5):691–699.
29.
Lynch RMShen TGnanakaran SDerdeyn CA. Appreciating HIV type 1 diversity: Subtype differences in EnvAIDS Res Hum Retroviruses2009253237-248. 29. Lynch RM, Shen T, Gnanakaran S, and Derdeyn CA: Appreciating HIV type 1 diversity: Subtype differences in Env. AIDS Res Hum Retroviruses 2009;25(3):237–248.
30.
Sagar MWu XLee SOverbaugh J. Human immunodeficiency virus type 1 V1–V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivityJ Virol200680199586-9598. 30. Sagar M, Wu X, Lee S, and Overbaugh J: Human immunodeficiency virus type 1 V1–V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006;80(19):9586–9598.
31.
Moore PLRanchobe NLambson BE et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infectionPLoS Pathog200959e1000598. 31. Moore PL, Ranchobe N, Lambson BE, et al.: Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 2009;5(9):e1000598.
32.
O'Rourke SMSchweighardt BPhung P et al. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virusJ Virol2010842111200-11209. 32. O'Rourke SM, Schweighardt B, Phung P, et al.: Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol 2010;84(21):11200–11209.
33.
Pinter AHonnen WJHe Y et al. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infectionJ Virol200478105205-5215. 33. Pinter A, Honnen WJ, He Y, et al.: The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004;78(10):5205–5215.
34.
Sagar M. HIV-1 transmission biology: Selection and characteristics of infecting virusesJ Infect Dis2010202Suppl 2S289-296. 34. Sagar M: HIV-1 transmission biology: Selection and characteristics of infecting viruses. J Infect Dis 2010;202(Suppl 2):S289–296.
35.
Chohan BLang DSagar M et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1–V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levelsJ Virol200579106528-6531. 35. Chohan B, Lang D, Sagar M, et al.: Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1–V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005;79(10):6528–6531.
36.
Derdeyn CADecker JMBibollet-Ruche F et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmissionScience200430356662019-2022. 36. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al.: Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004;303(5666):2019–2022.
37.
Wagner NLohler JKunkel EJ et al. Critical role for beta7 integrins in formation of the gut-associated lymphoid tissueNature19963826589366-370. 37. Wagner N, Lohler J, Kunkel EJ, et al.: Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature 1996;382(6589):366–370.
38.
von Andrian UHMackay CR. T-cell function and migration. Two sides of the same coinN Engl J Med2000343141020-1034. 38. von Andrian UH and Mackay CR: T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343(14):1020–1034.
39.
Parrish NFWilen CBBanks LB et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7PLoS Pathog201285e1002686. 39. Parrish NF, Wilen CB, Banks LB, et al.: Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog 2012;8(5):e1002686.
40.
Walker LMPhogat SKChan-Hui PY et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetScience20093265950285-289. 40. Walker LM, Phogat SK, Chan-Hui PY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326(5950):285–289.
41.
Zolla-Pazner SCardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designNat Rev Immunol2010107527-535. 41. Zolla-Pazner S and Cardozo T: Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol 2010;10(7):527–535.
42.
Changela AWu XYang Y et al. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1J Virol20118562524-2535. 42. Changela A, Wu X, Yang Y, et al.: Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol 2011;85(6):2524–2535.
43.
Moore PLGray ESSheward D et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loopJ Virol20118573128-3141. 43. Moore PL, Gray ES, Sheward D, et al.: Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 2011;85(7):3128–3141.
44.
Gorny MKStamatatos LVolsky B et al. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particlesJ Virol20057985232-5237. 44. Gorny MK, Stamatatos L, Volsky B, et al.: Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 2005;79(8):5232–5237.
45.
Honnen WJKrachmarov CKayman SC et al. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequenceJ Virol20078131424-1432. 45. Honnen WJ, Krachmarov C, Kayman SC, et al.: Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J Virol 2007;81(3):1424–1432.
46.
Robinson JEFranco KElliott DH et al. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4J Virol20108473443-3453. 46. Robinson JE, Franco K, Elliott DH, et al.: Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J Virol 2010;84(7):3443–3453.
47.
McLellan JSPancera MCarrico C et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Nature2011480336-343. 47. McLellan JS, Pancera M, Carrico C, et al.: Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011;480:336–343.
48.
Gorny MKMoore JPConley AJ et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1J Virol199468128312-8320. 48. Gorny MK, Moore JP, Conley AJ, et al.: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994;68(12):8312–8320.
49.
de Souza MSRatto-Kim SChuenarom W et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelopeJ Immunol2012188105166-5176. 49. de Souza MS, Ratto-Kim S, Chuenarom W, et al.: The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012;188(10):5166–5176.
50.
Rolland MLarsen BEdlefsen P. Sequence Analysis of HIV-1 Breakthrough Infections in the RV144 TrialPresented at AIDS Vaccine 2011Bangkok, ThailandSeptember12–152011Abstract. 50. Rolland M, Larsen B, and Edlefsen P: Sequence Analysis of HIV-1 Breakthrough Infections in the RV144 Trial. Presented at AIDS Vaccine 2011, Bangkok, Thailand, September 12–15, 2011. Abstract.
51.
Gaschen BTaylor JYusim K et al. Diversity considerations in HIV-1 vaccine selectionScience200229655772354-2360. 51. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296(5577):2354–2360.
52.
Sandberg MEriksson LJonsson J et al. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acidsJ Med Chem199841142481-2491. 52. Sandberg M, Eriksson L, Jonsson J, et al.: New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J Med Chem 1998;41(14):2481–2491.
53.
Droit ACheung CGottardo R. rMAT—an R/Bioconductor package for analyzing ChIP-chip experimentsBioinformatics2010265678-679. 53. Droit A, Cheung C, and Gottardo R: rMAT—an R/Bioconductor package for analyzing ChIP-chip experiments. Bioinformatics 2010;26(5):678–679.
54.
Robb MLRerks-Ngarm SNitayaphan S et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144Lancet Infect Dis2012127531-537. 54. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al.: Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012;12(7):531–537.
55.
Haynes BF. Case Control Study of the RV144 Trial for Immune Correlates: The Analysis Way ForwardPresented at AIDS Vaccine 2011Bangkok, ThailandSeptember12–152011. 55. Haynes BF: Case Control Study of the RV144 Trial for Immune Correlates: The Analysis and Way Forward. Presented at AIDS Vaccine 2011, Bangkok, Thailand, September 12–15, 2011.
56.
Liao H-XBonsignori MAlam SM et al. HIV-1 Envelope Antibodies Induced by ALVAC-AIDSVAX B/E Vaccine Target a Site of Vaccine Immune Pressure Within the C β Strand of gp120 V1V2Presented at Keystone Symposia 2012Keystone, ColoradoMarch21–262012Abstract. 56. Liao H-X, Bonsignori M, Alam SM, et al.: HIV-1 Envelope Antibodies Induced by ALVAC-AIDSVAX B/E Vaccine Target a Site of Vaccine Immune Pressure Within the C β Strand of gp120 V1V2. Presented at Keystone Symposia 2012, Keystone, Colorado, March 21–26, 2012. Abstract.
57.
Belhadj Jrad BBahraoui E. Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: Synthesis, reoxidation and purificationJ Pept Res1998515370-385. 57. Belhadj Jrad B and Bahraoui E: Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: Synthesis, reoxidation and purification. J Pept Res 1998;51(5):370–385.
58.
Misumi SEndo MMukai R et al. A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progressionJ Biol Chem20032783432335-32343. 58. Misumi S, Endo M, Mukai R, et al.: A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression. J Biol Chem 2003;278(34):32335–32343.
59.
Bogdanowich-Knipp SJJois DSSiahaan TJ. The effect of conformation on the solution stability of linear vs. cyclic RGD peptidesJ Pept Res1999535523-529. 59. Bogdanowich-Knipp SJ, Jois DS, and Siahaan TJ: The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. J Pept Res 1999;53(5):523–529.
60.
Mezo GMajer ZVass E et al. Conformational study of linear and cyclic peptides corresponding to the 276–284 epitope region of HSV gD-1Biophys Chem2003103151-65. 60. Mezo G, Majer Z, Vass E, et al.: Conformational study of linear and cyclic peptides corresponding to the 276–284 epitope region of HSV gD-1. Biophys Chem 2003;103(1):51–65.
61.
Hoogerhout PDonders EMvan Gaans-van den Brink JA et al. Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidisInfect Immun19956393473-3478. 61. Hoogerhout P, Donders EM, van Gaans-van den Brink JA, et al.: Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis. Infect Immun 1995;63(9):3473–3478.
62.
Beddows SLister SCheingsong R et al. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individualsJ Virol19997321740-1745. 62. Beddows S, Lister S, Cheingsong R, et al.: Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J Virol 1999;73(2):1740–1745.
63.
Abrahams MRAnderson JAGiorgi EE et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-Poisson distribution of transmitted variantsJ Virol20098383556-3567. 63. Abrahams MR, Anderson JA, Giorgi EE, et al.: Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-Poisson distribution of transmitted variants. J Virol 2009;83(8):3556–3567.
64.
Sagar MLaeyendecker OLee S et al. Selection of HIV variants with signature genotypic characteristics during heterosexual transmissionJ Infect Dis20091994580-589. 64. Sagar M, Laeyendecker O, Lee S, et al.: Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis 2009;199(4):580–589.
65.
Rong RBibollet-Ruche FMulenga J et al. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infectionJ Virol20078131350-1359. 65. Rong R, Bibollet-Ruche F, Mulenga J, et al.: Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 2007;81(3):1350–1359.
66.
Nawaz FCicala CVan Ryk D et al. The genotype of early-transmitting HIV gp120s promotes alphabeta-reactivity, revealing alphabetaCD4+ T cells as key targets in mucosal transmissionPLoS Pathog201172e1001301. 66. Nawaz F, Cicala C, Van Ryk D, et al.: The genotype of early-transmitting HIV gp120s promotes alphabeta-reactivity, revealing alphabetaCD4+ T cells as key targets in mucosal transmission. PLoS Pathog 2011;7(2):e1001301.
67.
Cicala CArthos JFauci AS. HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIVJ Transl Med20109Suppl 1S2. 67. Cicala C, Arthos J, and Fauci AS: HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med 2010;9(Suppl 1):S2.
68.
Israel ZRGorny MKPalmer C et al. Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individualsAIDS1997111128-130. 68. Israel ZR, Gorny MK, Palmer C, et al.: Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals. AIDS 1997;11(1):128–130.
69.
Kowalski MPotz JBasiripour L et al. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1Science198723748201351-1355. 69. Kowalski M, Potz J, Basiripour L, et al.: Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 1987;237(4820):1351–1355.
Information & Authors
Information
Published In
AIDS Research and Human Retroviruses
Volume 28 • Issue Number 11 • November 2012
Pages: 1444 - 1457
PubMed: 23035746
Copyright
Copyright 2012, Mary Ann Liebert, Inc.
History
Published online: 5 November 2012
Published in print: November 2012
Published ahead of print: 4 October 2012
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.